Last reviewed · How we verify
Nucleos(t)ide analogue therapy
Nucleos(t)ide analogues inhibit viral reverse transcriptase and/or polymerase, preventing viral DNA synthesis and replication.
Nucleos(t)ide analogues inhibit viral reverse transcriptase and/or polymerase, preventing viral replication by blocking the synthesis of viral nucleic acids. Used for HIV-1 infection (as part of combination antiretroviral therapy), Chronic hepatitis B infection.
At a glance
| Generic name | Nucleos(t)ide analogue therapy |
|---|---|
| Also known as | includes lamivudine, adefovir, entecavir, tenofovir or combinations thereof |
| Sponsor | Seng Gee Lim |
| Drug class | Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor |
| Target | Viral reverse transcriptase (HIV) or viral polymerase (HBV) |
| Modality | Small molecule |
| Therapeutic area | Virology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
These drugs are nucleotide or nucleoside mimics that incorporate into the growing viral DNA chain during replication, causing chain termination and blocking further synthesis. They are commonly used in chronic viral infections such as hepatitis B and HIV, where they suppress viral load by preventing the virus from copying its genetic material.
Approved indications
- Chronic hepatitis B
- HIV infection
Common side effects
- Lactic acidosis
- Hepatomegaly
- Nausea
- Headache
- Fatigue
Key clinical trials
- Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
- Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
- Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue (PHASE4)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection (PHASE1)
- A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy (PHASE2)
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) (PHASE3)
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) (PHASE3)
- Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB). (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nucleos(t)ide analogue therapy CI brief — competitive landscape report
- Nucleos(t)ide analogue therapy updates RSS · CI watch RSS
- Seng Gee Lim portfolio CI